SLS and ATNM Present Key Data Catalysts Ahead of AACR Summit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 20 2026
0mins
Source: stocktwits
- Optimistic Outlook for SLS009: Sellas is set to present preclinical AML data on SLS009 at the AACR meeting, demonstrating significant increases in cancer cell death in models with ASXL1 and TP53 mutations, which could attract investor attention and drive stock price appreciation.
- ATNM Data Highlights: Actinium will showcase new data from its Actinium-225 radiotherapy platform at AACR, particularly regarding ATNM-400 and Actimab-A across leukemia and solid tumor programs, potentially boosting market confidence in its treatment options.
- Analyst Target Discrepancies: According to consensus estimates from Koyfin, ATNM has a 12-month average analyst price target of $5.75, implying a 342% upside, while SLS's target is $8.67, suggesting about 66% upside, indicating a higher appeal for ATNM among investors.
- Retail Sentiment Comparison: On Stocktwits, retail sentiment for ATNM is deemed 'extremely bullish', while SLS appears 'bearish', which may influence investor decisions and market performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLS
Wall Street analysts forecast SLS stock price to fall
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.750
Low
7.00
Averages
7.25
High
7.50
Current: 7.750
Low
7.00
Averages
7.25
High
7.50
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sellas and 3D Medicines Arbitration Nears Ruling
- Arbitration Milestone: Following the final submissions on April 21, the arbitration case between Sellas and 3D Medicines is now in a 45-day window for formal closure under HKIAC rules, with a final ruling expected between July and September, which could significantly impact Sellas' future operations.
- Strong Financial Position: As of March 31, Sellas reported $107.1 million in cash and cash equivalents, having raised an additional $28.7 million from warrant exercises in April and May, providing robust funding for clinical trials and boosting investor confidence.
- Clinical Trial Progress: The Phase 3 Regal trial for GPS in acute myeloid leukemia patients has reached 78 out of the required 80 events, nearing the trigger for final analysis, and if successful, could extend median overall survival from 8 months to 12.6 months, representing significant market potential.
- Market Sentiment Shift: Despite a 465% surge in SLS stock over the past year, retail sentiment has turned 'bearish' amid a 50% increase in message volume over 24 hours, indicating heightened investor focus and uncertainty regarding the arbitration outcome.
See More
Sellas Life Sciences Strengthens Cash Reserves
- Cash Reserves Boost: Sellas Life Sciences reported cash and cash equivalents of $107.1 million as of March 31, 2026, and has since raised approximately $28.7 million through common stock warrant exercises, enhancing financial flexibility to achieve strategic milestones.
- Clinical Trial Progress: The late-stage Regal trial of Galinpepimut-S (GPS) in acute myeloid leukemia (AML) has recorded 78 out of the 80 events needed for final analysis, and the prolonged duration of the trial may indicate improved patient survival rates, boosting investor confidence.
- Market Sentiment Shift: Despite SLS shares dipping around 2.5%, investor sentiment on Stocktwits shifted from 'extremely bullish' to 'bullish', reflecting a focus on the results of ongoing trials and the belief that the company is laying the groundwork for a future AML franchise.
- Stock Performance: SLS shares have surged 224% year-to-date, and although there has been a short-term pullback, investors remain optimistic about the company's growth potential, particularly with upcoming clinical data for the SLS009 drug candidate.
See More
Sellas Life Sciences Gains Cramer’s Bullish Endorsement
- Cramer’s Endorsement: CNBC's Jim Cramer labeled Sellas Life Sciences as a 'great spec' during Mad Money, giving it 'two thumbs up,' which contributed to a 7% surge in the stock on Thursday and an additional 2% rise in pre-market trading on Friday.
- Regal Trial Data Imminent: The Phase 3 Regal trial evaluating GPS in AML patients is nearing critical data release, having reached 78 out of 80 events required for final analysis, with CEO Stergiou indicating a higher likelihood of extended survival outcomes than initially projected.
- Progress on SLS009: Beyond GPS, Sellas' second AML drug, SLS009, is also under investor scrutiny, with Stergiou highlighting its 'astonishing' activity in difficult-to-treat AML populations and expecting topline data later this year, which could further bolster investor confidence.
- Retail Investor Sentiment: Retail sentiment for SLS on Stocktwits has turned 'bullish,' with a 50% increase in message volume over 24 hours, reflecting positive market reactions to Cramer’s endorsement and suggesting increased investor interest in the stock.
See More
Investor Sentiments on Joby Aviation
- Investment Outlook: Joby Aviation is viewed as a promising investment, although market sentiment remains cautious; analysts suggest that the upcoming investment wave in the drone sector could benefit Joby significantly.
- Competitive Landscape: In the drone industry, analysts indicate that other companies may present more attractive investment opportunities, especially with the presidential election potentially driving further growth in the sector.
- Industry Dynamics: Despite Joby Aviation's strong stock performance, analysts express concerns about its profitability, noting that the company is still operating at a loss, which necessitates careful evaluation of its long-term value by investors.
- Investor Confidence Boost: As interest in drone technology rises, Joby Aviation's market visibility improves, leading analysts to adopt an optimistic stance on its future investment prospects, which may attract more investor attention.
See More
Sellas CEO Optimistic About GPS Data for NCCN Recognition
- Survival Data Highlights: Sellas reported that GPS treatment shows a median survival of 35.5 months in older AML patients, compared to just 5.4 months for those not receiving GPS, indicating significant potential for extending survival and possibly enhancing NCCN guideline recognition.
- Clinical Trial Progress: The Regal study has reached 78 events, nearing the trigger for final analysis, with CEO Stergiou noting that the trial's longer-than-expected duration may suggest positive survival outcomes, which is crucial for investor confidence.
- Positive Market Reaction: Sellas shares surged 6% on Wednesday and rose another 2% on Thursday, reflecting strong market anticipation for the upcoming Regal data, which is expected to further boost the company's stock price and market recognition.
- Therapeutic Potential: Stergiou highlighted that GPS could emerge as a maintenance therapy option for AML patients, particularly given the current lack of effective CR2 maintenance treatments, underscoring GPS's importance in addressing unmet medical needs.
See More
Sellas Life Sciences CEO Highlights New AML Treatment Data
- Survival Rates in AML: Recent data reveals that while 63% of high-risk elderly AML patients achieved remission at MD Anderson Cancer Center, only 15% proceeded to stem cell transplants, indicating a significant gap in effective treatment options that could hinder the company's therapeutic strategy.
- GPS Therapy Outlook: Sellas's GPS therapy demonstrated a median survival of 21 months in a similar elderly AML population, with CEO Stergiou emphasizing that this supports the upcoming Regal trial, which, if successful, could significantly enhance the company's market position in AML treatment.
- Potential of SLS009: Stergiou highlighted SLS009's strong activity in TP53-mutated and venetoclax-resistant AML patients, with topline data expected later this year, potentially providing a new growth avenue for the company and boosting investor confidence.
- Investor Sentiment Optimistic: With SLS stock surging 330% over the past year, retail sentiment on Stocktwits remains extremely bullish, reflecting strong market anticipation for Sellas's future developments, especially ahead of the upcoming Regal trial data release.
See More
Sellas and 3D Medicines Arbitration Nears Ruling
- Arbitration Milestone: Following the final submissions on April 21, the arbitration case between Sellas and 3D Medicines is now in a 45-day window for formal closure under HKIAC rules, with a final ruling expected between July and September, which could significantly impact Sellas' future operations.
- Strong Financial Position: As of March 31, Sellas reported $107.1 million in cash and cash equivalents, having raised an additional $28.7 million from warrant exercises in April and May, providing robust funding for clinical trials and boosting investor confidence.
- Clinical Trial Progress: The Phase 3 Regal trial for GPS in acute myeloid leukemia patients has reached 78 out of the required 80 events, nearing the trigger for final analysis, and if successful, could extend median overall survival from 8 months to 12.6 months, representing significant market potential.
- Market Sentiment Shift: Despite a 465% surge in SLS stock over the past year, retail sentiment has turned 'bearish' amid a 50% increase in message volume over 24 hours, indicating heightened investor focus and uncertainty regarding the arbitration outcome.
See More
Sellas Life Sciences Strengthens Cash Reserves
- Cash Reserves Boost: Sellas Life Sciences reported cash and cash equivalents of $107.1 million as of March 31, 2026, and has since raised approximately $28.7 million through common stock warrant exercises, enhancing financial flexibility to achieve strategic milestones.
- Clinical Trial Progress: The late-stage Regal trial of Galinpepimut-S (GPS) in acute myeloid leukemia (AML) has recorded 78 out of the 80 events needed for final analysis, and the prolonged duration of the trial may indicate improved patient survival rates, boosting investor confidence.
- Market Sentiment Shift: Despite SLS shares dipping around 2.5%, investor sentiment on Stocktwits shifted from 'extremely bullish' to 'bullish', reflecting a focus on the results of ongoing trials and the belief that the company is laying the groundwork for a future AML franchise.
- Stock Performance: SLS shares have surged 224% year-to-date, and although there has been a short-term pullback, investors remain optimistic about the company's growth potential, particularly with upcoming clinical data for the SLS009 drug candidate.
See More
Sellas Life Sciences Gains Cramer’s Bullish Endorsement
- Cramer’s Endorsement: CNBC's Jim Cramer labeled Sellas Life Sciences as a 'great spec' during Mad Money, giving it 'two thumbs up,' which contributed to a 7% surge in the stock on Thursday and an additional 2% rise in pre-market trading on Friday.
- Regal Trial Data Imminent: The Phase 3 Regal trial evaluating GPS in AML patients is nearing critical data release, having reached 78 out of 80 events required for final analysis, with CEO Stergiou indicating a higher likelihood of extended survival outcomes than initially projected.
- Progress on SLS009: Beyond GPS, Sellas' second AML drug, SLS009, is also under investor scrutiny, with Stergiou highlighting its 'astonishing' activity in difficult-to-treat AML populations and expecting topline data later this year, which could further bolster investor confidence.
- Retail Investor Sentiment: Retail sentiment for SLS on Stocktwits has turned 'bullish,' with a 50% increase in message volume over 24 hours, reflecting positive market reactions to Cramer’s endorsement and suggesting increased investor interest in the stock.
See More
Investor Sentiments on Joby Aviation
- Investment Outlook: Joby Aviation is viewed as a promising investment, although market sentiment remains cautious; analysts suggest that the upcoming investment wave in the drone sector could benefit Joby significantly.
- Competitive Landscape: In the drone industry, analysts indicate that other companies may present more attractive investment opportunities, especially with the presidential election potentially driving further growth in the sector.
- Industry Dynamics: Despite Joby Aviation's strong stock performance, analysts express concerns about its profitability, noting that the company is still operating at a loss, which necessitates careful evaluation of its long-term value by investors.
- Investor Confidence Boost: As interest in drone technology rises, Joby Aviation's market visibility improves, leading analysts to adopt an optimistic stance on its future investment prospects, which may attract more investor attention.
See More
Sellas CEO Optimistic About GPS Data for NCCN Recognition
- Survival Data Highlights: Sellas reported that GPS treatment shows a median survival of 35.5 months in older AML patients, compared to just 5.4 months for those not receiving GPS, indicating significant potential for extending survival and possibly enhancing NCCN guideline recognition.
- Clinical Trial Progress: The Regal study has reached 78 events, nearing the trigger for final analysis, with CEO Stergiou noting that the trial's longer-than-expected duration may suggest positive survival outcomes, which is crucial for investor confidence.
- Positive Market Reaction: Sellas shares surged 6% on Wednesday and rose another 2% on Thursday, reflecting strong market anticipation for the upcoming Regal data, which is expected to further boost the company's stock price and market recognition.
- Therapeutic Potential: Stergiou highlighted that GPS could emerge as a maintenance therapy option for AML patients, particularly given the current lack of effective CR2 maintenance treatments, underscoring GPS's importance in addressing unmet medical needs.
See More
Sellas Life Sciences CEO Highlights New AML Treatment Data
- Survival Rates in AML: Recent data reveals that while 63% of high-risk elderly AML patients achieved remission at MD Anderson Cancer Center, only 15% proceeded to stem cell transplants, indicating a significant gap in effective treatment options that could hinder the company's therapeutic strategy.
- GPS Therapy Outlook: Sellas's GPS therapy demonstrated a median survival of 21 months in a similar elderly AML population, with CEO Stergiou emphasizing that this supports the upcoming Regal trial, which, if successful, could significantly enhance the company's market position in AML treatment.
- Potential of SLS009: Stergiou highlighted SLS009's strong activity in TP53-mutated and venetoclax-resistant AML patients, with topline data expected later this year, potentially providing a new growth avenue for the company and boosting investor confidence.
- Investor Sentiment Optimistic: With SLS stock surging 330% over the past year, retail sentiment on Stocktwits remains extremely bullish, reflecting strong market anticipation for Sellas's future developments, especially ahead of the upcoming Regal trial data release.
See More
